160 related articles for article (PubMed ID: 31580466)
1. Health Outcomes and Direct Healthcare Costs in Patients with Melanoma: Associations with Level of Education.
Buja A; Rivera M; Zorzi M; Sperotto M; Baracco S; Italiano I; Vecchiato A; Del Fiore P; Avossa F; Corti MC; Guzzinati S; Saia M; Baldo V; Rugge M; Rossi CR
Acta Derm Venereol; 2020 Jan; 100(1):adv00003. PubMed ID: 31580466
[No Abstract] [Full Text] [Related]
2. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
3. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Buja A; Sartor G; Scioni M; Vecchiato A; Bolzan M; Rebba V; Sileni VC; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
Acta Derm Venereol; 2018 Feb; 98(2):218-224. PubMed ID: 29110018
[TBL] [Abstract][Full Text] [Related]
4. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
6. Estimation of direct costs of melanoma in the Veneto Region: a budget assessment and cost-consequence analysis.
Buja A; Sartor G; Scioni M; Girardi G; Vecchiato A; Bolzan M; Rebba V; Chiarion Sileni V; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
G Ital Dermatol Venereol; 2020 Dec; 155(6):764-771. PubMed ID: 30428652
[TBL] [Abstract][Full Text] [Related]
7. NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.
Adam J; Robertson J; Donegan E; Voicechovskaja I
Lancet Oncol; 2016 Nov; 17(11):1485-1486. PubMed ID: 27692478
[No Abstract] [Full Text] [Related]
8. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
9. Melanoma treatment costs: a systematic review of the literature, 1990-2011.
Guy GP; Ekwueme DU; Tangka FK; Richardson LC
Am J Prev Med; 2012 Nov; 43(5):537-45. PubMed ID: 23079178
[TBL] [Abstract][Full Text] [Related]
10. Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis.
Serra-Arbeloa P; Rabines-Juárez ÁO; Álvarez-Ruiz MS; Guillén-Grima F
Actas Dermosifiliogr; 2017 Apr; 108(3):229-236. PubMed ID: 27887672
[TBL] [Abstract][Full Text] [Related]
11. The cost of unresectable stage III or stage IV melanoma in Italy.
Maio M; Ascierto P; Testori A; Ridolfi R; Bajetta E; Queirolo P; Guida M; Romanini A; Chiarion-Sileni V; Pigozzo J; Di Giacomo AM; Calandriello M; Didoni G; van Baardewijk M; Konto C; Lucioni C
J Exp Clin Cancer Res; 2012 Nov; 31(1):91. PubMed ID: 23116062
[TBL] [Abstract][Full Text] [Related]
12. An estimate of the annual direct cost of treating cutaneous melanoma.
Tsao H; Rogers GS; Sober AJ
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):669-80. PubMed ID: 9591809
[TBL] [Abstract][Full Text] [Related]
13. Association of the Affordable Care Act's Medicaid expansion with the diagnosis and treatment of clinically localized melanoma: A National Cancer Database study.
Straker RJ; Song Y; Shannon AB; Chu EY; Miura JT; Ming ME; Karakousis GC
J Am Acad Dermatol; 2021 Jun; 84(6):1628-1635. PubMed ID: 33549653
[TBL] [Abstract][Full Text] [Related]
14. An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil.
Souza RJ; Mattedi AP; Rezende ML; Corrêa Mde P; Duarte EM
An Bras Dermatol; 2009 Jul; 84(3):237-43. PubMed ID: 19668936
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
Chevalier J; Bonastre J; Avril MF
Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
Gordon LG; Brynes J; Baade PD; Neale RE; Whiteman DC; Youl PH; Aitken JF; Janda M
Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
[TBL] [Abstract][Full Text] [Related]
17. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
18. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
Lyth J; Carstensen J; Synnerstad I; Lindholm C
J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
[TBL] [Abstract][Full Text] [Related]
19. Quality management of cutaneous melanoma: impact on short-term outcomes and costs.
Buja A; De Luca G; Zorzi M; Carpin E; Pinato C; Vecchiato A; Del Fiore P; Bortolami A; Tognazzo S; Falasco F; Saia M; Baldo V; Rugge M; Rossi CR; Mocellin S
Eur J Dermatol; 2021 Dec; 31(6):730-735. PubMed ID: 34789442
[TBL] [Abstract][Full Text] [Related]
20. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
